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On the multiple roles of the voltage
gated sodium channel β1 subunit in
genetic diseases
Debora Baroni and Oscar Moran*
Istituto di Biofisica – Consiglio Nazionale delle Ricerche, Genova, Italy
Voltage-gated sodium channels are intrinsic plasma membrane proteins that initiate the
action potential in electrically excitable cells. They are composed of a pore-forming
α-subunit and associated β-subunits. The β1-subunit was the first accessory subunit
to be cloned. It can be important for controlling cell excitability and modulating multiple
aspects of sodium channel physiology. Mutations of β1 are implicated in a wide variety of
inherited pathologies, including epilepsy and cardiac conduction diseases. This review
summarizes β1-subunit related channelopathies pointing out the current knowledge
concerning their genetic background and their underlying molecular mechanisms.
Keywords: voltage-gated sodiumchannel, channelopathies, epilepsy, cardiopathies, β1-subunit, GEFS+, Brugada
syndrome
Introduction
Action potentials play a central role in most excitable cells, as neurons, skeletal and cardiac muscle,
and endocrine cells. Action potential generation and propagation occur through, and are regulated
by the function of voltage-gated sodium channels (NaCh), proteins with selective pores for sodium
ions that span the cell membrane. In mammals, NaCh are heterotrimeric complexes composed
of a pore-forming α-subunit (∼260 kDa), a non-covalently associated β1- or β3-subunit and a
covalently associated β2- or β4-subunit (Messner and Catterall, 1985; Catterall, 2012).
There are nine NaChs α-subunit pore-forming isoforms encoded by diﬀerent genes, termed
Nav1.1 to Nav1.9, and an atypical non-voltage-dependent one, named NavX (Catterall, 2012).
In humans, Nav1.1, Nav1.2, Nav1.3, and Nav1.6 are abundantly expressed in the central nervous
system (CNS) and in the peripheral nervous system (PNS); Nav1.1 and Nav1.6 are also expressed in
adult ventricular myocytes. Nav1.4 is abundant in adult skeletal muscle while Nav1.5 is expressed
predominantly in heart. Nav1.7, Nav1.8, and Nav1.9 are preponderantly located in the PNS
(Table 1). The α-subunit isoforms show a high degree of amino-acid sequence identity. Vertebrate
α-subunits contain four homologous but non-identical domains (I–IV), each of which contains
six transmembrane segments (S1–S6). The residues between S5 and S6 form the channel pore
(P-loop) and control ion selectivity and permeation. Positively charged S4 segments act as voltage
sensors.
To date, ﬁve β-subunits have been identiﬁed in mammals: β1, its alternative splice variant β1B
(previously called β1A), β2, β3, and β4. Each β-subunit is encoded by one of four genes, SCN1B–
SCN4B. As well as α-subunits, β-subunits are highly expressed in excitable cells, including central
and peripheral neurons, skeletal and cardiac muscle cells. They are also expressed in non-excitable
cells such as astrocytes, radial glia, and Bergmann glia (Table 1).
β-subunits (∼30–40 kDa) are single pass molecules with an extracellular N-terminus, a
transmembrane-spanning segment, and an intracellular C-terminus. The β1B-subunit arising from
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TABLE 1 | Types of human sodium channels (NaCh) α and β subunits and their tissue distribution.
Gene Chromosome Protein Uniprot code∗ Tissue expression
α-subunits
SCN1A 2q24.3 Nav1.1 or α1.1 P35498 Cell bodies of central neurons, T-tubules in myocytes axon initial segments
SCN2A 2q24.3 Nav1.2 or α1.2 Q99250 Central neurons, mainly localizated in unmyelinated and premyelinated axons
SCN3A 2q24.3 Nav1.3 or α1.3 Q9NY46 Cell bodies of central neurons, cardiac myocytes
SCN4A 17q23.3 Nav1.4 or α1.4 P35499 Skeletal muscles
SCN5A 3p21-22 Nav1.5 or α1.5 Q86V90 Cardiac myocytes, immature and denervated skeletal muscles, certain brain
neurons
SCN8A 12q13 Nav1.6 or α1.6 Q9UQD0 Somatodendritic distribution in output neurons of cerebellum, cerebral cortex,
hippocampus; Purkinje cells in cerebellar granule cell layer, astrocytes,
Schwann cells, axon initial segments, dorsal root ganglia, nodes of Ranvier in
peripheral and central nervous systems, T-tubules in cardiac myocytes
SCN9A 2q24 Nav1.7 or α1.6 Q15858 Dorsal root ganglia neurons, sympathetic neurons, Schwann cells,
neuroendocrine cells
SCN10A 3p22.2 Nav1.8 or α1.8 Q9Y5Y9 Dorsal root ganglia neurons, human heart, intracardiac neurons
SCN11A 3p22.2 Nav1.9 or α1.9 Q9UI33 C-type neurons in dorsal root ganglia
SCN7A 2q24.3 NavX Q01118 Dorsal root ganglia neurons, hippocampus, thalamus, cerebellum, median
preoptic nucleus, circumventricular organs, Peripheral nervous system (PNS),
heart, skeletal muscle, uterusβ-subunits
SCN1B 19q13.1 SCN1b or β1 Q07699 Ubiquitous: central and peripheral neurons, glia, skeletal and cardiac muscles
SCN1B 19q13.1 SCN1bB or β1B Cortical neurons, Cerebellar Purkinje cells, Deep cerebellar nuclei, Ventral horn
neurons, Dorsal root ganglia neurons, peripheral nerves
SCN2B 11q23 SCN2b or β2 Q5U0K8 Central and peripheral neurons, glia, cardiac muscles
SCN3B 11q23.3 SCN3Bor β3 Q9NY72 Central and peripheral neurons, adrenal glands, kidney
SCN4B 11q23.3 SCN4b or β4 Q8IWT1 Central and peripheral neurons, glia, skeletal and cardiac muscles
Modified from Patiño et al. (2009) and Catterall (2012).
∗http://www.uniprot.org
the retention of a segment of intron 3 (exon 3A) does not include
neither the transmembrane nor the intracellular domains, being
a soluble protein (Qin et al., 2003; Patiño et al., 2009).
β1- and β3-subunits, which share 57% sequence homology,
associate non-covalently with the α-subunits (Isom et al., 1992;
McCormick et al., 1998; Morgan et al., 2000; Meadows et al.,
2001; Spampanato et al., 2004), whereas β2- and β4-subunits,
which have a high sequence homology, are covalently bound to
the α-subunits by a disulphide bond (McCormick et al., 1998; Yu
et al., 2003; Spampanato et al., 2004). All ﬁve β-subunits contain
an extracellular immunoglobulin-like (Ig) domain homologous
to V-type Ig-loop motif present in the Ig superfamily of cell
adhesion molecules (CAMs), with a noteworthy homology to the
CAM myelin P0 glycoprotein (Isom and Catterall, 1996; Morgan
et al., 2000; Yu et al., 2003), a structural feature that enables
them to function as CAMs (Isom et al., 1995a; Brackenbury and
Isom, 2011; Calhoun and Isom, 2014). This protein motif has
been conﬁrmed in the crystallographic studies of the extracel-
lular domain of the β3- and β4-subunits (Gilchrist et al., 2013;
Namadurai et al., 2014).
Many studies have tried to demonstrate that β-subunits are
able to ﬁne-tune gating and kinetics of α-subunits expressed
heterologously. There is no doubt that the classical roles of
β-subunits as “conducing” modulators of Na+ current is of
paramount importance in regulating ion ﬂux and cell excitability.
However, there is a clear trend in literature that underlines the
importance of β-subunit “non-conducing” functions, including
NaCh cell surface expression regulation, migration and pathﬁnd-
ing, cell adhesion and putative transcriptional modulation
(Davis et al., 2004; Brackenbury et al., 2008, 2010; Baroni
et al., 2013, 2014; Baroni and Moran, 2015). Furthermore,
β-subunits are key players in a variety of pathologies, includ-
ing epilepsy, cardiac arrhythmia, neuropsychiatric disorders,
neuropathic and inﬂammatory pain, and cancer (Brackenbury
and Isom, 2011). Thus, the understanding of the interac-
tions between NaCh α- and β-subunits is of predominant
importance, also in view of the exploitation of their therapeutic
potential.
In this review we will focus on the multiple roles played
by the β1-subunit, which has been the ﬁrst ancillary subunit
to be cloned and to be associated to human diseases. We will
describe its mutations and illustrate some hypotheses formulated
to attempt the explanation of the mechanisms that lead to β1
mutation-related pathologies.
β1 Functions
From its molecular identiﬁcation (Isom et al., 1992), the β1-
subunit has been proposed to modulate gating and kinetics
properties of NaCh, especially inactivation. Co-expression of
rat β1-subunit with skeletal muscle or brain rat α-subunits in
Xenopus oocytes has been proposed to increase the amplitude
of the peak sodium current, accelerate inactivation, and shift the
voltage-dependence of inactivation to more negative membrane
potentials (Isom et al., 1992; Patton et al., 1994; Moran and Conti,
2001). However, data regarding the heterologous expression of
β1 in mammalian cells are contradictory and diﬀerent results
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have been described by diﬀerent groups. It was reported that,
in mammalian cells, the β1-subunit is able: to shift the inactiva-
tion curve to positive, negative or to not change the potential,
to shift the activation curve to negative potentials or to not
change it, to hasten the recovery from inactivation or to not
change it, to increase or do not modify the density of sodium
currents (Bendahhou et al., 1995; Isom et al., 1995b; Hayward
et al., 1996; An et al., 1998; Kazen-Gillespie et al., 2000; Tammaro
et al., 2002; Moran et al., 2003). It has also been proposed that
β1-subunit modulates NaCh gating through the screening of
the membrane surface charge (Johnson et al., 2004; Ferrera and
Moran, 2006).
Beside the regulation of NaCh gating, it has been proposed
that β1-subunit participates in cell–cell and cell–matrix adhesion,
contributing to cellular aggregation, ankyrin recruitment, and
neurite outgrowth (Srinivasan et al., 1998; Malhotra et al., 2000,
2002; Kazarinova-Noyes et al., 2001; Ratcliﬀe et al., 2001; Davis
et al., 2004; McEwen et al., 2004). Finally, it was demonstrated
that in excitable cells the β1-protein acts as a crucial element
in the assembly and cell surface expression of the heteromeric
complex of the sodium channel, determining the type and the
amount of α-subunit to be expressed (Patiño et al., 2009). Indeed,
over-expression and silencing of the NaCh accessory subunit,
demonstrate that the β1 is able to regulate the NaCh expres-
sion, and it is also a key factor in the processes that determine
which α-subunit is going to be expressed (Baroni et al., 2013,
2014).
Consistently with these properties, β1-subunit was
demonstrated able to rescue traﬃcking-deﬁcient Nav1.1
channels to the cell surface, thus inﬂuencing the disease severity
caused by the lack of a properly functional NaCh α-subunit
(Rusconi et al., 2007, 2009; Sugiura et al., 2012; Thompson et al.,
2012; Bechi et al., 2015). Also in this case, disease severity may be
severely inﬂuenced by the total or partial lack of the β1-subunit
capability to traﬃc mutant Nav1.1 to the cell surface.
β1-Linked Diseases
One of the most remarkable ﬁndings of research on the molecu-
lar properties of NaCh β1-subunit was the discovery that its
mutations cause inherited diseases that selectively aﬀect the CNS
or the heart (Wallace et al., 1998; Antzelevitch, 2003; Fish and
Antzelevitch, 2003; Watanabe et al., 2008; Escayg and Goldin,
2010). Unfortunately, the comprehension of the molecular
mechanisms underlying the SCN1B mutation physiopathology
is limited by the lack of a unique and exhaustive elucidation
of the role played by this protein on the regulation of the
NaCh. Evidences collected up to now suggest a model in which
gene dosage may determine the severity of disease (Moran and
Conti, 2001). For example, for SCN1B mutations related to CNS
diseases, a single mutant allele may result in the development of a
milder disease like generalized epilepsy with febrile seizures plus.
In contrast, expression of two non-functional SCN1B alleles may
result a more severe epileptic disease like the Dravet Syndrome.
Another peculiarity that distinguishes SCN1B mutations
linked either to CNS or to cardiac diseases is that, with the
exception of the recently identiﬁedmutation G257R (Patiño et al.,
2009) which is located in the β1B retained intronic region, all
generalized epilepsy with febrile seizures plus (GEFS+) causing
mutations are localized in the Ig-loop region (Figure 1), suggest-
ing that the cell adhesion functions mediated by this region are
clinically relevant (Brackenbury and Isom, 2011).
The inherited diseases caused by mutations in the NaCh β1-
subunit described so far are:
1. Generalized Epilepsy with Febrile Seizures
Plus (GEFS+)
Somemutations in SCN1B are linked to GEFS+ (OMIM:604233),
an autosomal dominant inherited epilepsy. The ﬁrst SCN1B
mutation identiﬁed in GEFS+ was C121W (Wallace et al., 1998,
2002), caused by a 387C-to-G transversion in SCN1B gene. As a
consequence, a key disulphide bond involved in maintaining the
extracellular Ig-like loop is disrupted (Barbieri et al., 2012).
Functional studies of mutant rat C121W β1-subunit co-
expressed with either with brain 1.2 or muscle 1.4 rat α-subunits
in Xenopus laevis oocytes showed that the mutated β1-subunit
loses its ability to modulate the acceleration of the inacti-
vation rate of the sodium channel compared with wild type
(WT) β1-subunit (Wallace et al., 1998; Moran and Conti,
2001). Interestingly, C121W-β1 heterologous expression in
mammalian cells yielded contradictory results, depending on
the α-subunit co-expressed and on the expression system.
When co-expressed with human Nav1.3, human C121W-β1
causes a rightward shift of inactivation compared to the
WT-β1, potentially increasing channel excitability (Meadows
et al., 2002). On the contrary, when rat C121W-β1 is co-
expressed with rat skeletal muscle Nav1.4, sodium channels
recover more slowly from fast inactivation (Tammaro et al.,
2002).
It has been argued that C121W-β1 acts as a dominant-
negative subunit, competing with the WT-β1-subunit in the
regulation of the NaCh α-subunit expression and activity (Moran
and Conti, 2001; Meadows et al., 2002). In rat neuronal-like
cells, the regulatory eﬀect of the over-expression of rat β1-
subunit on the α-subunit mRNA, protein and Na+ current
levels is abolished by the epileptogenic C121W-β1; conversely,
in rat cardiac cells mutation C121W does not alter the β1-
subunit modulation of NaCh (Baroni et al., 2013). These ﬁndings
demonstrate the tissue-speciﬁcity of the modulation of NaCh
expression.
Successively, six other mutations, I70_E74del, R85C, R85H,
G257R, R125L, and D25N were associated to GEFS+, R85C,
and R85H are missense mutations of an evolutionary conserved
arginine residue in the Ig-loop (Scheﬀer et al., 2007). When
co-expressed with human Nav1.2, human R85H-β1 appeared
to modulate the voltage-dependence of NaCh slow inactiva-
tion without any eﬀect on other electrophysiological parameters,
while co-expression of human Nav1.2 with human R85C-β1
had no detectable eﬀects on any channel property, suggest-
ing a complete loss of function mutant (Xu et al., 2007).
Immunohistochemical studies on cells transiently transfected
with β1 mutants R85C and R85H failed to detect them at the cell
surface, indicating that they are traﬃcking defective (Xu et al.,
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FIGURE 1 | Disease-linked mutations of voltage-gated sodium channel β1- and β1B-subunits. Mutated residues associated with epilepsy (green), cardiac
diseases (red) or both (blue) are marked. The disulphide bridge involving residue C121 is indicated as a broken line.
2007). Conversely, in surface biotinylation assay, similarly toWT-
β1, human β1-R85H was detected at the cell surface of stably
transfected Chinese hamster lung 1610 cells (Patiño et al., 2011),
pointing out the need for further investigations on the cellular
localization of this mutant.
Unlike the other GEFS+- associated SCN1B mutations, that
are located in the Ig-domain, the missense mutation G257R is
located in the β1B retained intronic region (Patiño et al., 2011).
Surface biotinylation assay revealed that diﬀerently from Chinese
hamster lung 1610 cells stably transfected with human WT-
β1, Chinese hamster lung 1610 cells permanently transfected
with human G257R fail to show the mutant β1 at the plasma
membrane (Patiño et al., 2011).
Mutation I70_E74del is a A-to-C transversion in the splice
acceptor site of exon 3 of SCN1B gene, resulting in a deletion
of ﬁve amino acids within the extracellular Ig-fold (Audenaert
et al., 2003). Unfortunately, no functional data are available for
this mutation. R125L is a GEFS+-associated mutation, caused by
a 374G-to-T transversion in exon 3 of SCN1B gene. It determines
the substitution of a highly conserved arginine in the extracellu-
lar domain of the protein (Fendri-Kriaa et al., 2011). Even though
functional studies on this mutation are still not available, it can
be hypothesized thatmutation R125L causes electrostatic changes
and a loss of hydrogen bonding in the Ig-loop region aﬀecting the
structure and stability of the protein. The last GEFS+-associated
SCN1B mutation is D25N. This missense mutation is due to
a 73G-to-A transversion in exon 2 of SCN1B and causes the
neutralization of an charged residue in the Ig-loop (Orrico et al.,
2009).
2. Dravet Syndrome (DS)
Dravet syndrome or severe myoclonic epilepsy of infancy
(OMIM:607208) is a severe form of generalized epilepsy with
febrile seizures, characterized by generalized tonic, clonic, and
tonic–clonic seizures triggered at ﬁrst by fever, arising shortly
after birth. Cognitive development is normal until ∼2 years
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of age, when it slows or stagnates (Dravet, 1978; Wolﬀ et al.,
2006). Classically, DS is considered to be a SCN1A-linked disease
(Oguni et al., 2005; Korﬀ and Nordli, 2006). However, a small but
growing number of DS patients aﬀected by mutations in SCN1B
has been described. Diﬀerently from GEFS+, all the SCN1B
mutations causing DS have been found in homozygosis.
The ﬁrst SCN1B mutation identiﬁed in DS is R125C, which
prevents normal traﬃcking of β1 to the cell surface and thus
results in a functional null phenotype (Patiño et al., 2009).
Chinese hamster lung 1610 cells stably transfected with the rat
Nav1.2 subunit as well HEK cells permanently transfected with
human Nav1.1 were further stably transfected with human WT-
or R125C-β1. Western-blot analysis of cell fractions unequivo-
cally demonstrated that humanR125C is ineﬃciently expressed at
the cell surface at physiological temperatures, but the overcome of
this traﬃcking defect at a lower temperature permits the mutant
β1-subunit to be fully capable of modulating sodium current
(Patiño et al., 2009). Another SCN1B mutation linked to DS,
I106F, is caused by a 316A>T nucleotide change resulting in
residue substitution in the Ig-loop (Ogiwara et al., 2012). No
functional data are available for this mutant protein.
Mouse models support the link between SCN1B and epilepsy.
Scn1b-null mice have frequent spontaneous generalized seizures,
display aberrant neuronal excitability, and have defects in
neuronal development (Chen et al., 2004; Brackenbury et al.,
2013). Importantly, abnormalities in brain development are
observed at P5, prior to seizure onset, suggesting that structural
alterations, aberrant cell adhesive interactions, and abnormal
excitability early in development may be causative factors in
epileptogenesis (Brackenbury et al., 2013). A knock-in mouse
model of C121W-mediated GEFS+ displays hyper-excitability in
speciﬁc sub-populations of central neurons, reduced dendritic
arborisation of subicular pyramidal neurons, and increased
susceptibility to febrile seizures (Wimmer et al., 2010; Hatch et al.,
2014).
3. Brugada Syndrome (BrS)
Brugada syndrome (BrS) is a condition characterized by a
distinct ST-segment elevation in the right precordial leads of
the electrocardiogram and by an increased risk of cardiac
arrhythmia and sudden death (Brugada and Brugada, 1992).
The condition predominantly exhibits an autosomal dominant
pattern of inheritance and incomplete penetrance. It has an
average prevalence of 5:10000 worldwide, and is much more
common in men than in women (Priori et al., 2002; Smits
et al., 2002; Antzelevitch, 2003). The mean age of BrS clinical
debut is 40 years; however, the ﬁrst occurrence of symptoms
may occur in early childhood or old age (Antzelevitch, 2003).
Currently, BrS is associated to more than 100 mutations in seven
genes (SCN5A, GPD1L, CACNA1C, CACNB2, KCNE3, SCN3B),
including SCN1B.
E87Q is the ﬁrst β1 mutation linked to BrS (BrS5,
OMIM:612838), caused by a 259G-C transversion in exon 3 of the
human SCN1B gene. It results in a substitution of the neutraliza-
tion of a highly conserved glutamic acid within the Ig-loop, which
is common to both the β1 and β1B transcripts. Functional studies
of the E87Q mutation in transiently transfected CHO cells show
that the co-expression of mutant human β1 or β1B with human
cardiac Nav1.5 neither increases the sodium current nor produces
a negative shift in the voltage dependence of the activation curve
with respect to cells transfected with WT-β1 or -β1B and Nav 1.5.
Mutant E87Q-β1 or -β1B shifted only the voltage dependence of
inactivation to negative potentials (Watanabe et al., 2008).
Another mutation linked to BrS is W179X that has been
found in β1B. It is a non-sense mutation caused by a 536G-
A transition in exon 3A of the SCN1B gene (Watanabe et al.,
2008). A variant of this mutation, produced by a 537G-A
transition, also causes the W179X mutation. This variant has
been correlated with cardiac conduction defects without any
BrS symptom (Watanabe et al., 2008). It is conceivable that
the lack of a β1 protein causes a disease by simply haploin-
suﬃciency. Functional studies of W179X mutation showed
that the co-expression of human W179X-β1B with human
cardiac Nav1.5 failed to increase sodium currents and did
not modulate the activation and inactivation (Watanabe et al.,
2008).
The BrS linked-mutation, R214Q, has been found in exon
3A of β1B-subunit (Hu et al., 2012) It is due to a 641G-to-A
transversion. Sodium currents of cells transfected with human
SCN5A and SCN1Bb-R214Q resulted 56.5% smaller than that of
SCN5A plus SCN1Bb-WT and 33.05% smaller than that of cells
transfected with the sole SCN5A. Furthermore, R214Q caused no
signiﬁcant shift in steady-state inactivation and activation, but
slowed recovery from inactivation (Hu et al., 2012).
SCN1B BrS-linked H162P mutation was found in a Danish
patient by Holst et al. (2012). As the patient did not completely
fulﬁll the diagnostic criteria for BrS and no functional data are
available, further investigations would be mandatory to conﬁrm
the clinical relevance of this mutant.
Finally two SCN1B mutations, V138I and T189M, have
been related to sudden unexplained nocturnal death syndrome
(SUNDS), a disorder whose electrocardiogram (ECG) character-
istics and clinical phenotype are very similar to BrS (Liu et al.,
2014).
4. Atrial Arrhythmias
R85H and D153N are SCN1B mutations that have been associ-
ated with familiar atrial ﬁbrillation (ATFB13 OMIM:615377).
R85H is located in the Ig-loop, and thus aﬀects both β1 and β1B.
Conversely, D153N is located in exon 4 of SCN1B and thus can
only aﬀect β1. Both mutations result in a reduction of sodium
currents in heterologous expression systems. In comparison with
human WT-β1 co-expressed with human SCN5A in CHO cells,
D153N does not aﬀect the sodium channel activation or inacti-
vation. However, R85H resulted in a positive shift of voltage-
dependence of both, activation and inactivation (Watanabe et al.,
2009).
R85H, has been also reported as an epilepsy mutation in
patients from two families without history of seizure disorders
(Scheﬀer et al., 2007). Further functional studies would be
mandatory to conﬁrm the clinical relevance of this mutant, that
represents an exception among SCN1B mutations. In fact all
the SCN1B mutations identiﬁed so far have demonstrated to
selectively aﬀect the CNS or the heart.
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5. Long QT- Syndrome (LQTS)
Long QT- syndrome (LQTS) is a cardiovascular disorder associ-
ated with syncopal episodes, torsades de pointes, ventricular
ﬁbrillation, and sudden death. This syndrome is characterized
by prolonged QT-interval in the ECG because of an abnormal-
ity in cardiac repolarization. At least 15 forms of LQTS have
been identiﬁed, each with speciﬁc associated genes, variations in
penetrance, allele dominance, and co-morbidities.
A recent report identiﬁed mutation P213T of β1B to
cause LQTS (OMIM: 611819; Giudicessi and Ackerman,
2013). When heterologously co-expresed in HEK cells, both
human β1B-WT and β1B-P213T increased sodium currents
with respect to expression of human Nav1.5 alone. The
activation voltage dependence curve was signiﬁcantly shifted
to the left in cells co-expressing Nav1.5 and β1B-P213T
compared with Nav1.5 β1B-WT, while the inactivation voltage
dependence curve was not aﬀected by the mutation. P213T
of β1B signiﬁcantly accelerates the recovery from inactiva-
tion. Furthermore, the probability of having more channels
in the slow inactivated state resulted signiﬁcantly lower for
Nav1.5β1B-P213T than for Nav1.5 β1B-WT. This change
could lead to higher channel availability, unbalancing the
currents that determine the duration of action potentials,
and determining the condition for LQTS onset (Riuró et al.,
2014).
Evidence in transgenic mice suggests that β1 subunit is
involved in normal cardiac function and that mutations of
SCN1B can result in disease. Consistent with LQTS, Scn1b-
null mice have abnormal cardiac action potentials evidenced
by prolonged QT intervals that persist after pharmacological
autonomic blockade (Lopez-Santiago et al., 2007). Scn1b-null
ventricular myocytes also display increased peak and persistent
Na+ current relative to WT cells (Lopez-Santiago et al., 2007).
Concluding Remarks
A growing list of SCN1B mutations linked to inherited diseases
reveals the important roles that the β1-subunit plays in the NaCh-
function. β1-subunit channelopathies belong to two categories:
epileptic syndromes and cardiac arrhythmias. Each SCN1B
mutation seems to have a tissue-selectivity whose molecular
mechanism is far to be elucidated. Another peculiarity is the wide
spectrum of phenotypes and clinical manifestations that can be
observed in patients aﬀected by the same SCN1Bmutation.
The comprehension of the pathophysiology of diseases
caused by mutations of β1-subunit is severely limited by the
understanding of the functional role of the β1-subunit. The β1-
subunit was recognized as a part of the NaCh complex since
the early attempts to identify the molecules that compose this
channel. However, even though the molecular identiﬁcation of
the β1-subunit, and the possibility to express it in heterol-
ogous systems, the role of this protein is still controversial.
The β1-subunit could play three diﬀerent roles. It has been
claimed that β1-subunit is involved in the ﬁne tuning of the
NaCh gating. This proposal comes from the heterologous expres-
sion of β1-subunit in Xenopus oocytes, where it dramatically
regulates the NaCh inactivation. However, when the β1-subunit
is heterologously expressed in mammalian cells results are
contradictory, and, in general, its role seems to be correlated
to an indirect eﬀect by charge surface modiﬁcations and not
to a speciﬁc NaCh modulation. The second possible role of
the β1-subunit is associated to the interactions of the NaCh
with the cytoskeleton and the extracellular matrix, determin-
ing the correct docking of the NaCh in speciﬁc regions of
the plasma membrane. A further role in modulating the gene
expression, and therefore the amount and quality of NaCh
α-subunits has been also recently illustrated. All three possible
roles could be implicated in the genesis of the diseases caused
by β1-subunit mutations but none of these hypotheses has been
incontrovertibly demonstrated yet. As occurs with any biolog-
ical mechanism with a high degree of complexity, one could
hypothesize that other genes – for example, genes encoding some
of the β1-subunit interacting proteins, may likely exert their
inﬂuence on the severity of the diseases linked to β1-subunit
mutations or determine the tissue-speciﬁcity. The disclosure of
this speciﬁc genetic relationships will not only shed new light
on the biology of NaCh heteromeric complex but also provide
critical information to design more appropriate pharmacological
therapies.
Acknowledgment
This work was partially supported by Fondazione Compagnia di
San Paolo.
References
An, R., Wang, X., Kerem, B., Benhorin, J., Medina, A., Goldmit, M., et al.
(1998). Novel LQT-3 mutation aﬀects Na+ channel activity throught
interactions between α- and β1-subunits. Circ. Res. 83, 141–146. doi:
10.1161/01.RES.83.2.141
Antzelevitch, C. (2003). Brugada syndrome: clinical, genetic, molecular,
cellular and ionic aspects. Expert Rev. Cardiovasc. Ther. 1, 177–185. doi:
10.1586/14779072.1.2.177
Audenaert, D., Claes, L., Ceulemans, B., Löfgren, A., Van Broeckhoven, C.,
and De Jonghe, P. (2003). A deletion in SCN1B is associ-
ated with febrile seizures and early-onset absence epilepsy.
Neurology 61, 854–856. doi: 10.1212/01.WNL.0000080362.55
784.1C
Barbieri, R., Baroni, D., and Moran, O. (2012). Identiﬁcation of an intra-molecular
disulﬁde bond in the sodium channel β1-subunit. Biochem. Biophys. Res.
Commun. 420, 364–367. doi: 10.1016/j.bbrc.2012.02.163
Baroni, D., Barbieri, R., Picco, C., and Moran, O. (2013). Functional modulation
of voltage-dependent sodium channel expression by wild type and mutated
C121W-β1 subunit. J. Bioenerg. Biomembr. 45, 353–368. doi: 10.1007/s10863-
013-9510-3
Baroni, D., and Moran, O. (2015). Diﬀerential gene expression proﬁles
of two excitable rat cell lines after over-expression of WT- and
C121W-β1 sodium channel subunits. J. Neurosc. 297, 105–117. doi:
10.1016/j.neuroscience.2015.03.052
Baroni, D., Picco, C., Barbieri, R., and Moran, O. (2014). Antisense-mediated post-
transcriptional silencing of SCN1B gene modulates sodium channel functional
expression. Biol. Cell 106, 13–29. doi: 10.1111/boc.201300040
Frontiers in Pharmacology | www.frontiersin.org 6 May 2015 | Volume 6 | Article 108
Baroni and Moran Sodium channel β1 subunit
Bechi, G., Rusconi, R., Cestèle, S., Striano, P., Franceschetti, S., Mantegazza, M.
(2015). Rescuable folding defective NaV1.1 (SCN1A) mutants in epilepsy:
properties, occurrence, and novel rescuing strategy with peptides
targeted to the endoplasmic reticulum. Neurobiol. Dis. 75, 100–114. doi:
10.1016/j.nbd.2014.12.028
Bendahhou, S., Cummins, T., Potts, J., Tong, J., and Agnew, W. (1995). Serine-
1321-independent regulation of the μ1 adult skeletal muscle Na+ channel
by protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 92, 12003–12007. doi:
10.1073/pnas.92.26.12003
Brackenbury, W. J., Calhoun, J. D., Chen, C., Miyazaki, H., Nukina, N., Oyama, F.,
et al. (2010). Functional reciprocity between Na+ channel Nav1.6 and beta1
subunits in the coordinated regulation of excitability and neurite outgrowth.
Proc. Natl. Acad. Sci. U.S.A. 107, 2283–2288. doi: 10.1073/pnas.0909434107
Brackenbury,W. J., Djamgoz, M. B. A., and Isom, L. L. (2008). An emerging role for
voltage-gated Na+ channels in cellular migration: regulation of central nervous
system development and potentiation of invasive cancers. Neuroscientist 14,
571–583. doi: 10.1177/1073858408320293
Brackenbury, W. J., and Isom, L. L. (2011). Na channel β subunits: overachievers of
the ion channel family. Front. Pharmacol. 2:53. doi: 10.3389/fphar.2011.00053
Brackenbury, W. J., Yuan, Y., O’Malley, H. A., Parent, J. M., and Isom, L. L. (2013).
Abnormal neuronal patterning occurs during early postnatal brain develop-
ment of Scn1b-null mice and precedes hyperexcitability. Proc. Natl. Acad. Sci.
U.S.A. 110, 1089–1094. doi: 10.1073/pnas.1208767110
Brugada, P., and Brugada, J. (1992). Right bundle branch block, persistent ST
segment elevation and sudden cardiac death: a distinct clinical and electrocar-
diographic syndrome. Amulticenter report. J. Am. Coll. Cardiol. 20, 1391–1396.
doi: 10.1016/0735-1097(92)90253-J
Calhoun, J. D., and Isom, L. L. (2014). The role of non-pore-forming β subunits
in physiology and pathophysiology of voltage-gated sodium channels. Handb.
Exp. Pharmacol. 221, 51–89. doi: 10.1007/978-3-642-41588-3_4
Catterall, W. A. (2012). Voltage-gated sodium channels at 60: structure,
function and pathophysiology. J. Physiol. 590, 2577–2589. doi:
10.1113/jphysiol.2011.224204
Chen, C., Westenbroek, R. E., Xu, X., Edwards, C. A., Sorenson, D. R., Chen, Y.,
et al. (2004). Mice lacking sodium channel beta1 subunits display defects
in neuronal excitability, sodium channel expression, and nodal architecture.
J. Neurosci. 24, 4030–4042. doi: 10.1523/JNEUROSCI.4139-03.2004
Davis, T. H., Chen, C., and Isom, L. L. (2004). Sodium channel beta1 subunits
promote neurite outgrowth in cerebellar granule neurons. J. Biol. Chem. 279,
51424–51432. doi: 10.1074/jbc.M410830200
Dravet, C. (1978). Les epilepsies graves de l’enfant. Vie Med. 8, 543–548.
Escayg, A., and Goldin, A. L. (2010). Sodium channel SCN1A and epilepsy:
mutations and mechanisms. Epilepsia 51, 1650–1658. doi: 10.1111/j.1528-
1167.2010.02640.x
Fendri-Kriaa, N., Kammoun, F., Salem, I. H., Kifagi, C., Mkaouar-Rebai, E.,
Hsairi, I., et al. (2011). New mutation c.374C>T and a putative disease-
associated haplotype within SCN1B gene in Tunisian families with febrile
seizures. Eur. J. Neurol. 18, 695–702. doi: 10.1111/j.1468-1331.2010.03216.x
Ferrera, L., and Moran, O. (2006). Beta1-subunit modulates the Nav1.4 sodium
channel by changing the surface charge. Exp. Brain Res. 172, 139–150. doi:
10.1007/s00221-005-0323-4
Fish, J. M., and Antzelevitch, C. (2003). Cellular and ionic basis for the sex-
related diﬀerence in the manifestation of the Brugada syndrome and progres-
sive conduction disease phenotypes. J. Electrocardiol. 36(Suppl), 173–179. doi:
10.1016/j.jelectrocard.2003.09.054
Gilchrist, J., Das, S., Van Petegem, F., and Bosmans, F. (2013). Crystallographic
insights into sodium-channel modulation by the β4 subunit. Proc.
Natl. Acad. Sci. U.S.A. 110, E5016–E5024. doi: 10.1073/pnas.13145
57110
Giudicessi, J. R., and Ackerman, M. J. (2013). Determinants of incomplete
penetrance and variable expressivity in heritable cardiac arrhythmia syndromes.
Transl. Res. 161, 1–14. doi: 10.1016/j.trsl.2012.08.005
Hatch, R. J., Reid, C. A., and Petrou, S. (2014). Enhanced in vitro CA1 network
activity in a sodium channel β1(C121W) subunit model of genetic epilepsy.
Epilepsia 55, 601–608. doi: 10.1111/epi.12568
Hayward, L., Brown, R. Jr., and Cannon, S. (1996). Inactivation defects caused
by myotonia-associated mutations in the sodium channel III-IV linker. J. Gen.
Physiol. 107, 559–576. doi: 10.1085/jgp.107.5.559
Holst, A. G., Saber, S., Houshmand, M., Zaklyazminskaya, E. V., Wang, Y., Jensen,
H. K., et al. (2012). Sodium current and potassium transient outward current
genes in Brugada syndrome: screening and bioinformatics. Can. J. Cardiol. 28,
196–200. doi: 10.1016/j.cjca.2011.11.011
Hu, D., Barajas-Martínez, H., Medeiros-Domingo, A., Crotti, L., Veltmann, C.,
Schimpf, R., et al. (2012). A novel rare variant in SCN1Bb linked to Brugada
syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel
currents. Heart Rhythm 9, 760–769. doi: 10.1016/j.hrthm.2011.12.006
Isom, L., and Catterall, W. (1996). Na+ channel subunits and ig domains. Nature
383, 307–308. doi: 10.1038/383307b0
Isom, L. L., De Jongh, K. S., Patton, D. E., Reber, B. F., Oﬀord, J., Charbonneau, H.,
et al. (1992). Primary structure and functional expression of the beta
1 subunit of the rat brain sodium channel. Science 256, 839–842. doi:
10.1126/science.1375395
Isom, L., Ragsdale, D., De Jongh, K., Westenbroek, R., Reber, B., Scheuer, T.,
et al. (1995a). Structure and function of the beta 2 subunit of brain sodium
channels, a transmembrane glycoprotein with CA motif. Cell 83, 433–442. doi:
10.1016/0092-8674(95)90121-3
Isom, L., Scheuer, T., Brownstein, A., Ragsdale, D., Murphy, B., and Catterall, W.
(1995b). Functional coexpression of the β1 and type IIA α subunits of
sodium channels in mammalian cell line. J. Biol. Chem. 270, 3306–3312. doi:
10.1074/jbc.270.7.3306
Johnson, D., Montpetit, M. L., Stocker, P. J., and Bennett, E. S. (2004). The sialic
acid component of the beta1 subunit modulates voltage-gated sodium channel
function. J. Biol. Chem. 279, 44303–44310. doi: 10.1074/jbc.M408900200
Kazarinova-Noyes, K., Malhotra, J. D., McEwen, D. P., Mattei, L. N., Berglund,
E. O., Ranscht, B., et al. (2001). Contactin associates with Na+ channels and
increases their functional expression. J. Neurosci. 21, 7517–7525.
Kazen-Gillespie, K., Ragsdale, D., D’Andrea, M., Mattei, L., Rogers, K., and Isom, L.
(2000). Cloning, localization, and functional expression of sodium channel
beta1A subunits. J. Biol. Chem. 275, 1079–1088. doi: 10.1074/jbc.275.2.1079
Korﬀ, C. M., and Nordli, D. R. J. (2006). Epilepsy syndromes undetermined
whether focal or generalized in infants. Epilepsy Res. 70(Suppl. 1), S105–S109.
doi: 10.1016/j.eplepsyres.2005.11.013
Liu, C., Tester, D. J., Hou, Y., Wang, W., Lv, G., Ackerman, M. J., et al. (2014). Is
sudden unexplained nocturnal death syndrome in Southern China a cardiac
sodium channel dysfunction disorder? Forensic Sci. Int. 236, 38–45. doi:
10.1016/j.forsciint.2013.12.033
Lopez-Santiago, L. F., Meadows, L. S., Ernst, S. J., Chen, C., Malhotra, J. D.,
McEwen, D. P., et al. (2007). Sodium channel Scn1b null mice exhibit
prolonged QT and RR intervals. J. Mol. Cell Cardiol. 43, 636–647. doi:
10.1016/j.yjmcc.2007.07.062
Malhotra, J. D., Kazen-Gillespie, K., Hortsch, M., and Isom, L. L. (2000).
Sodium channel beta subunits mediate homophilic cell adhesion and recruit
ankyrin to points of cell-cell contact. J. Biol. Chem. 275, 11383–11388. doi:
10.1074/jbc.275.15.11383
Malhotra, J. D., Koopmann, M. C., Kazen-Gillespie, K. A., Fettman, N.,
Hortsch, M., and Isom, L. L. (2002). Structural requirements for interaction of
sodium channel beta 1 subunits with ankyrin. J. Biol. Chem. 277, 26681–26688.
doi: 10.1074/jbc.M202354200
McCormick, K., Isom, L., Ragsdale, D., Smith, D., Scheuer, T., and Catterall, W.
(1998). Molecular determinants of the Na+ channel function in the extracel-
lular domain of the b1 subunit. J. Biol. Chem. 273, 3954–3962. doi:
10.1074/jbc.273.7.3954
McEwen, D. P., Meadows, L. S., Chen, C., Thyagarajan, V., and Isom, L. L. (2004).
Sodium channel beta1 subunit-mediated modulation of Nav1.2 currents and
cell surface density is dependent on interactions with contactin and ankyrin.
J. Biol. Chem. 279, 16044–16049. doi: 10.1074/jbc.M400856200
Meadows, L. S., Malhotra, J., Loukas, A., Thyagarajan, V., Kazen-Gillespie, K. A.,
Koopman, M. C., et al. (2002). Functional and biochemical analysis of a sodium
channel beta1 subunit mutation responsible for generalized epilepsywith febrile
seizures plus type 1. J. Neurosci. 22, 10699–10709.
Meadows, L., Malhotra, J. D., Stetzer, A., Isom, L. L., and Ragsdale, D. S. (2001).
The intracellular segment of the sodium channel beta 1 subunit is required
for its eﬃcient association with the channel alpha subunit. J. Neurochem. 76,
1871–1878. doi: 10.1046/j.1471-4159.2001.00192.x
Messner, D., and Catterall, W. (1985). The sodium channel from rat brain.
Separation and characterisation of subunits. J. Biol. Chem. 260, 10597–10604.
Frontiers in Pharmacology | www.frontiersin.org 7 May 2015 | Volume 6 | Article 108
Baroni and Moran Sodium channel β1 subunit
Moran, O., and Conti, F. (2001). Skeletal muscle sodium channel is aﬀected by
an epileptogenic β1 subunit mutation. Biochem. Biophys. Res. Commun. 282,
55–59. doi: 10.1006/bbrc.2001.4502
Moran, O., Conti, F., and Tammaro, P. (2003). Sodium channel heterol-
ogous expression in mammalian cells and the role of the endogenous
β1-subunits. Neurosci. Lett. 336, 175–179. doi: 10.1016/S0304-3940(02)
01284-3
Morgan, K., Stevens, E., Shah, B., Cox, P., Dixon, A., Lee, K., et al. (2000). β3:
an additional auxiliary subunit of the voltage-sensitive sodium channel that
modulates channel gating with distinct kinetics. Proc. Natl. Acad. Sci. U.S.A.
97, 2308–2313. doi: 10.1073/pnas.030362197
Namadurai, S., Balasuriya, D., Rajappa, R., Wiemhöfer, M., Stott, K., Klingauf, J.,
et al. (2014). Crystal structure and molecular imaging of the Nav channel β3
subunit indicates a trimeric assembly. J. Biol. Chem. 289, 10797–10811. doi:
10.1074/jbc.M113.527994
Ogiwara, I., Nakayama, T., Yamagata, T., Ohtani, H., Mazaki, E., Tsuchiya, S.,
et al. (2012). A homozygous mutation of voltage-gated sodium channel β(I)
gene SCN1B in a patient with Dravet syndrome. Epilepsia 53, e200–e203. doi:
10.1111/epi.12040
Oguni, H., Hayashi, K., Osawa, M., Awaya, Y., Fukuyama, Y., Fukuma, G.,
et al. (2005). Severe myoclonic epilepsy in infancy: clinical analysis and
relation to SCN1A mutations in a Japanese cohort. Adv. Neurol. 95,
103–117.
Orrico, A., Galli, L., Grosso, S., Buoni, S., Pianigiani, R., Balestri, P., et al. (2009).
Mutational analysis of the SCN1A, SCN1B and GABRG2 genes in 150 Italian
patients with idiopathic childhood epilepsies. Clin. Genet. 75, 579–581. doi:
10.1111/j.1399-0004.2009.01155.x
Patiño, G. A., Brackenbury, W. J., Bao, Y., Lopez-Santiago, L. F., O’Malley,
H. A., Chen, C., et al. (2011). Voltage-gated Na+ channel β1B: a secreted cell
adhesion molecule involved in human epilepsy. J. Neurosci. 31, 14577–14591.
doi: 10.1523/JNEUROSCI.0361-11.2011
Patiño, G. A., Claes, L. R. F., Lopez-Santiago, L. F., Slat, E. A., Dondeti,
R. S. R., Chen, C., et al. (2009). A functional null mutation of SCN1B
in a patient with Dravet syndrome. J. Neurosci. 29, 10764–10778. doi:
10.1523/JNEUROSCI.2475-09.2009
Patton, D., Isom, L., Catterall, W., and Goldin, A. (1994). The adult rat brain b1
subunit modiﬁes activation and inactivation gating of multiple sodium channel
α subunits. J. Biol. Chem. 269, 17640–17655.
Priori, S. G., Napolitano, C., Gasparini, M., Pappone, C., Della Bella, P.,
Giordano, U., et al. (2002). Natural history of Brugada syndrome: insights
for risk stratiﬁcation and management. Circulation 105, 1342–1347. doi:
10.1161/hc1102.105288
Qin, N., D’Andrea, M. R., Lubin, M., Shafaee, N., Codd, E. E., and Correa,
A. M. (2003). Molecular cloning and functional expression of the human
sodium channel beta1B subunit, a novel splicing variant of the beta1
subunit. Eur. J. Biochem. 270, 4762–4770. doi: 10.1046/j.1432-1033.2003.
03878.x
Ratcliﬀe, C. F., Westenbroek, R. E., Curtis, R., and Catterall, W. A. (2001). Sodium
channel beta1 and beta3 subunits associate with neurofascin through their
extracellular immunoglobulin-like domain. J. Cell Biol. 154, 427–434. doi:
10.1083/jcb.200102086
Riuró, H., Campuzano, O., Arbelo, E., Iglesias, A., Batlle, M., Pérez-Villa, F.,
et al. (2014). A missense mutation in the sodium channel β1b subunit reveals
SCN1B as a susceptibility gene underlying long QT syndrome. Heart Rhythm
11, 1202–1209. doi: 10.1016/j.hrthm.2014.03.044
Rusconi, R., Combi, R., Cestèle, S., Grioni, D., Franceschetti, S., Dalprà, L., et al.
(2009). A rescuable folding defective Nav1.1 (SCN1A) sodium channel mutant
causes GEFS+: common mechanism in Nav1.1 related epilepsies?Hum. Mutat.
30, E747–E760. doi: 10.1002/humu.21041
Rusconi, R., Scalmani, P., Cassulini, R. R., Giunti, G., Gambardella, A.,
Franceschetti, S., et al. (2007). Modulatory proteins can rescue a traﬃcking
defective epileptogenic Nav1.1 Na+ channel mutant. J. Neurosci. 27, 11037–
11046. doi: 10.1523/JNEUROSCI.3515-07.2007
Scheﬀer, I. E., Harkin, L. A., Grinton, B. E., Dibbens, L. M., Turner, S. J.,
Zielinski, M. A., et al. (2007). Temporal lobe epilepsy and GEFS+ phenotypes
associated with SCN1B mutations. Brain 130, 100–109. doi: 10.1093/brain/
awl272
Smits, J. P. P., Eckardt, L., Probst, V., Bezzina, C. R., Schott, J. J., Remme,C. A., et al.
(2002). Genotype-phenotype relationship in Brugada syndrome: electrocardio-
graphic features diﬀerentiate SCN5A-related patients from non-SCN5A-related
patients. J. Am. Coll. Cardiol. 40, 350–356. doi: 10.1016/S0735-1097(02)01962-9
Spampanato, J., Aradi, I., Soltesz, I., and Goldin, A. L. (2004). Increased neuronal
ﬁring in computer simulations of sodium channel mutations that cause general-
ized epilepsy with febrile seizures plus. J. Neurophysiol. 91, 2040–2050. doi:
10.1152/jn.00982.2003
Srinivasan, J., Schachner, M., and Catterall, W. (1998). Interaction of voltage-
gated sodium channels with the extracellular matrix molecules tenascin-
C and tenascin-R. Proc. Natl. Acad. Sci. U.S.A. 95, 15753–15757. doi:
10.1073/pnas.95.26.15753
Sugiura, Y., Ogiwara, I., Hoshi, A., Yamakawa, K., Ugawa, Y. (2012). Diﬀerent
degrees of loss of function between GEFS+ and SMEI Nav 1.1 missense
mutants at the same residue induced by rescuable folding defects. Epilepsia. 53,
e111–e114. doi: 10.1111/j.1528-1167.2012.03467.x
Tammaro, P., Conti, F., and Moran, O. (2002). Modulation of sodium current
in mammalian cells by an epilepsy-correlated β1-subunit mutation. Biochem.
Biophys. Res. Commun. 291, 1095–1101. doi: 10.1006/bbrc.2002.6570
Thompson, C. H., Porter, J. C., Kahlig, K. M., Daniels, M. A., and George, A. L. J.
(2012). Nontruncating SCN1A mutations associated with severe myoclonic
epilepsy of infancy impair cell surface expression. J. Biol. Chem. 287, 42001–
42008. doi: 10.1074/jbc.M112.421883
Wallace, R. H., Scheﬀer, I. E., Parasivam, G., Barnett, S., Wallace, G. B.,
Sutherland, G. R., et al. (2002). Generalized epilepsy with febrile seizures plus:
mutation of the sodium channel subunit SCN1B.Neurology 58, 1426–1429. doi:
10.1212/WNL.58.9.1426
Wallace, R., Wang, D., Singh, R., Scheﬀer, I., George, A., Phillips, H., et al. (1998).
Febrile seizures and generalized epilepsy associated with mutation of the Na+-
channels β1-subunit gene SCN1B. Nat. Genet. 19, 366–370. doi: 10.1038/448
Watanabe, H., Darbar, D., Kaiser, D.W., Jiramongkolchai, K., Chopra, S., Donahue,
B. S., et al. (2009). Mutations in sodium channel β1- and β2-subunits associ-
ated with atrial ﬁbrillation. Circ. Arrhythm. Electrophysiol. 2, 268–275. doi:
10.1161/CIRCEP.108.779181
Watanabe, H., Koopmann, T. T., Le Scouarnec, S., Yang, T., Ingram, C. R.,
Schott, J., et al. (2008). Sodium channel beta1 subunit mutations associated with
Brugada syndrome and cardiac conduction disease in humans. J. Clin. Invest.
118, 2260–2268. doi: 10.1172/JCI33891
Wimmer, V. C., Reid, C. A., Mitchell, S., Richards, K. L., Scaf, B. B., Leaw, B. T., et al.
(2010). Axon initial segment dysfunction in a mouse model of genetic epilepsy
with febrile seizures plus. J. Clin. Invest. 120, 2661–2671. doi: 10.1172/JCI42219
Wolﬀ, M., Cassé-Perrot, C., and Dravet, C. (2006). Severe myoclonic epilepsy of
infants (Dravet syndrome): natural history and neuropsychological ﬁndings.
Epilepsia 47(Suppl. 2), 45–48. doi: 10.1111/j.1528-1167.2006.00688.x
Xu, R., Thomas, E. A., Gazina, E. V., Richards, K. L., Quick, M., Wallace, R. H.,
et al. (2007). Generalized epilepsy with febrile seizures plus-associated sodium
channel beta1 subunit mutations severely reduce beta subunit-mediated
modulation of sodium channel function. Neuroscience 148, 164–174. doi:
10.1016/j.neuroscience.2007.05.038
Yu, F. H., Westenbroek, R. E., Silos-Santiago, I., McCormick, K. A., Lawson, D.,
Ge, P., et al. (2003). Sodium channel beta4, a new disulﬁde-linked auxiliary
subunit with similarity to beta2. J. Neurosci. 23, 7577–7585.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Baroni andMoran. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribu-
tion or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 8 May 2015 | Volume 6 | Article 108
